For the first time, we are pleased to present our research from three different targets to address chronic skin conditions in the dermatology community both through long-term HUMIRA
research and new investigational agents risankizumab and upadacitinib.
The 48-week data indicated that the product is equivalent, with no clinically meaningful differences in efficacy, safety and immunogenicity to Humira
in people with moderately-to-severely active rheumatoid arthritis (RA), including in patients who moved from Humira
to Cyltezo at week 24.
The green lights clear the way for biosimilar copies of Humira
to be launched in Europe in due course, although lawyers do not expect that to happen before October 2018, given the patents protecting adalimumab.
11 last year for Humira
Pen, which is indicated for rheumatoid arthritis, psoriatic arthritis, anky-losing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis.
Most recently the Food and Drug Administration accepted for review an application from Boehringer Ingelheim for BI 695501, its biosimilar to Humira
-- the leading inflammation drug, with analysts projecting $17 billion in sales next year -- is in a slightly better position than its competitors, with sales volumes still rising.
As with Humira
, "the most common expected adverse reactions with Amjevita are infections and injection site reactions," the FDA said.
targets and helps block TNF-alpha, a specific source of inflammation that can have a role in uveitis.
amp;nbsp;Food and Drug Administration approved Humira
, manufactured by AbbVie, for the treatment of uveitis in June this year.
(adalimumab) is approved for use in a range of chronic inflammatory conditions such as plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease and juvenile idiopathic arthritis.
A spokesman claimed England was "now one of the few countries in the world" that does not use drugs like Humira
and Remicade for uveitis".
1) And AbbVie (a spinoff of Abbott Laboratories) makes so much money on Humira
that it was able to afford more than $200 million in advertising for that one drug alone in a recent year (2012).